Oncolytics Biotech Income Statement Analysis

Revenue, earnings, and profit margins in millions CAD

Scroll to see more
Oncolytics Biotech Inc. income statement - Annual data in millions CAD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue0.000.000.000.000.000.000.00
Cost of Revenue0.000.000.000.000.000.000.00
Gross Profit0.000.000.000.000.000.000.00
Operating Expenses
Research & Development21.6517.7115.4312.9212.9410.8210.03
Selling, General & Administrative13.3416.0811.4912.8612.510.000.00
Operating Expenses34.9833.7926.9226.2425.4620.3817.27
Operating Income-34.98-33.79-26.92-26.24-25.46-20.38-17.27
Other Income/Expense
Interest Income1.201.330.530.100.120.000.17
Interest Expense0.000.000.000.000.000.000.00
Other Income/Expense3.405.29-0.02-0.122.83-12.930.61
Income
Income Before Tax-31.58-27.66-24.75-26.26-22.51-33.12-16.49
Income Tax Expense0.130.100.080.050.000.000.55
Net Income-31.71-27.75-24.84-26.30-22.51-33.12-17.04
Net Income - Continuous Operations-31.71-27.75-24.84-26.300.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA-34.88-33.71-26.83-25.78-25.01-32.64-17.18
EBIT-31.58-33.79-26.92-26.24-25.46-33.12-17.27
Depreciation & Amortization0.100.080.090.450.090.000.00
Earnings Per Share
Basic EPS-----1.00-1.00-1.00
Diluted EPS-----1.00-1.00-1.00
Basic Shares Outstanding76.4867.6258.0353.5140.3422.1416.02
Diluted Shares Outstanding76.4867.6258.0353.5140.3422.1416.02